-
Something wrong with this record ?
Efficacy and safety of switching to iGlarLixi from premixed insulins in people with type 2 diabetes: The Soli-SWITCH study
M. Haluzík, K. Cypryk, A. Alvarez, F. Lauand, V. Corp Dit Genti, OS. Bakiner, S. Lim
Language English Country England, Great Britain
Document type Journal Article, Clinical Trial, Phase IV, Multicenter Study
Grant support
Sanofi
PubMed
40098261
DOI
10.1111/dom.16276
Knihovny.cz E-resources
- MeSH
- Diabetes Mellitus, Type 2 * drug therapy blood MeSH
- Adult MeSH
- Drug Combinations MeSH
- Glycated Hemoglobin analysis MeSH
- Hypoglycemia chemically induced MeSH
- Hypoglycemic Agents * administration & dosage adverse effects therapeutic use MeSH
- Insulin Glargine * administration & dosage adverse effects therapeutic use MeSH
- Blood Glucose drug effects MeSH
- Middle Aged MeSH
- Humans MeSH
- Drug Substitution * MeSH
- Peptides * administration & dosage adverse effects therapeutic use MeSH
- Glucagon-Like Peptide-2 Receptor MeSH
- Drug Administration Schedule MeSH
- Aged MeSH
- Treatment Outcome MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Clinical Trial, Phase IV MeSH
- Multicenter Study MeSH
AIMS: To assess the efficacy and safety of switching from premixed insulin to a once-daily, fixed-ratio combination of insulin glargine 100 U/mL + lixisenatide (iGlarLixi) in people with type 2 diabetes (T2D). METHODS: In this phase 4, 24-week, single-arm study, participants switched from once-daily or twice-daily premixed insulin to iGlarLixi (EudraCT number 2021-003711-25). Key inclusion criteria: ≥18 years; premixed insulin therapy for ≥3 months and < 10 years; ± 1-2 oral antidiabetic drugs (OADs); HbA1c ≥7.5% to ≤10.0%. The primary endpoint was the change in HbA1c from baseline to Week 24. Secondary endpoints included: participants achieving HbA1c <7% and change in body weight at Week 24, and safety. RESULTS: Overall, 162 participants switched to iGlarLixi (89.5% from twice-daily premixed insulin); mean duration of diabetes was 15.7 (standard deviation [SD]: 8.3) years. Mean baseline HbA1c (8.5%) reduced by least squares (LS) mean of 1.2% (95% confidence interval [CI]: -1.4, -1.1) at Week 24, and 37.6% of participants had achieved an HbA1c target of <7% (95% CI: 30.0, 45.7). LS mean body weight change from baseline to Week 24 was -1.0 kg (95% CI: -1.6, -0.5). Fasting and post-prandial plasma glucose decreased from baseline to Week 24 by 45.6 mg/dL (SD ± 52.4) and 67.6 mg/dL (SD ± 65.1), respectively. Confirmed symptomatic hypoglycaemia occurred in 38.3% of participants (ADA level 1: 35.8%; level 2: 15.4%; level 3: 0.0%). CONCLUSIONS: iGlarLixi initiation was associated with improved glycaemic control, without body weight gain or increased hypoglycaemia over 24 weeks.
Adana Dr Turgut Noyan Training and Research Hospital Endocrinology Baskent University Adana Turkey
Department of Internal Diseases and Diabetology Medical University of Lodz Lodz Poland
Diabetes Centre Institute for Clinical and Experimental Medicine Prague Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25015911
- 003
- CZ-PrNML
- 005
- 20250731091341.0
- 007
- ta
- 008
- 250708s2025 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/dom.16276 $2 doi
- 035 __
- $a (PubMed)40098261
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Haluzík, Martin $u Diabetes Centre, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic $1 https://orcid.org/0000000202016888 $7 xx0000707
- 245 10
- $a Efficacy and safety of switching to iGlarLixi from premixed insulins in people with type 2 diabetes: The Soli-SWITCH study / $c M. Haluzík, K. Cypryk, A. Alvarez, F. Lauand, V. Corp Dit Genti, OS. Bakiner, S. Lim
- 520 9_
- $a AIMS: To assess the efficacy and safety of switching from premixed insulin to a once-daily, fixed-ratio combination of insulin glargine 100 U/mL + lixisenatide (iGlarLixi) in people with type 2 diabetes (T2D). METHODS: In this phase 4, 24-week, single-arm study, participants switched from once-daily or twice-daily premixed insulin to iGlarLixi (EudraCT number 2021-003711-25). Key inclusion criteria: ≥18 years; premixed insulin therapy for ≥3 months and < 10 years; ± 1-2 oral antidiabetic drugs (OADs); HbA1c ≥7.5% to ≤10.0%. The primary endpoint was the change in HbA1c from baseline to Week 24. Secondary endpoints included: participants achieving HbA1c <7% and change in body weight at Week 24, and safety. RESULTS: Overall, 162 participants switched to iGlarLixi (89.5% from twice-daily premixed insulin); mean duration of diabetes was 15.7 (standard deviation [SD]: 8.3) years. Mean baseline HbA1c (8.5%) reduced by least squares (LS) mean of 1.2% (95% confidence interval [CI]: -1.4, -1.1) at Week 24, and 37.6% of participants had achieved an HbA1c target of <7% (95% CI: 30.0, 45.7). LS mean body weight change from baseline to Week 24 was -1.0 kg (95% CI: -1.6, -0.5). Fasting and post-prandial plasma glucose decreased from baseline to Week 24 by 45.6 mg/dL (SD ± 52.4) and 67.6 mg/dL (SD ± 65.1), respectively. Confirmed symptomatic hypoglycaemia occurred in 38.3% of participants (ADA level 1: 35.8%; level 2: 15.4%; level 3: 0.0%). CONCLUSIONS: iGlarLixi initiation was associated with improved glycaemic control, without body weight gain or increased hypoglycaemia over 24 weeks.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a diabetes mellitus 2. typu $x farmakoterapie $x krev $7 D003924
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 12
- $a hypoglykemika $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D007004
- 650 12
- $a inzulin glargin $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D000069036
- 650 _2
- $a glykovaný hemoglobin $x analýza $7 D006442
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a krevní glukóza $x účinky léků $7 D001786
- 650 12
- $a náhrada léků $7 D057915
- 650 12
- $a peptidy $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D010455
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a hypoglykemie $x chemicky indukované $7 D007003
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a rozvrh dávkování léků $7 D004334
- 650 _2
- $a fixní kombinace léků $7 D004338
- 650 _2
- $a receptor pro glukagonu podobný peptid 2 $7 D000067758
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a klinické zkoušky, fáze IV $7 D017429
- 655 _2
- $a multicentrická studie $7 D016448
- 700 1_
- $a Cypryk, Katarzyna $u Department of Internal Diseases and Diabetology, Medical University of Lodz, Lodz, Poland
- 700 1_
- $a Alvarez, Agustina $u Sanofi, Madrid, Spain
- 700 1_
- $a Lauand, Felipe $u Sanofi, Paris, France
- 700 1_
- $a Corp Dit Genti, Valérie $u Sanofi, Paris, France
- 700 1_
- $a Bakiner, Okan Sefa $u Adana Dr. Turgut Noyan Training and Research Hospital, Endocrinology, Baskent University, Adana, Turkey
- 700 1_
- $a Lim, Soo $u Department of Internal Medicine, Seoul National University College of Medicine and Seoul National University Bundang Hospital, Seongnam, Republic of Korea $1 https://orcid.org/0000000241371671
- 773 0_
- $w MED00005425 $t Diabetes, obesity and metabolism $x 1463-1326 $g Roč. 27, č. 5 (2025), s. 2730-2739
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/40098261 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250708 $b ABA008
- 991 __
- $a 20250731091336 $b ABA008
- 999 __
- $a ok $b bmc $g 2366625 $s 1253036
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 27 $c 5 $d 2730-2739 $e 20250317 $i 1463-1326 $m Diabetes, obesity and metabolism $n Diabetes Obes Metab $x MED00005425
- GRA __
- $p Sanofi
- LZP __
- $a Pubmed-20250708
